MICROLEARNING Optimal Risk Stratification and Combination Therapy: Improving Outcomes in PAH
CE Information
0.25 CME creditsCompletion Time
15 minutesAvailable Until
February 19, 2027Posted By
QDCME
Navigate
Overview
Specialties
Acute CareSubspecialties
Emergency and Respiratory/PulmonologyClinical Topics
PAH (Pulmonary Arterial Hypertension) and Primary CarePulmonary arterial hypertension (PAH) is a rare, progressive subtype of pulmonary hypertension characterized by narrowing and remodeling of the small pulmonary arteries, which leads to elevated pulmonary vascular resistance, increased pulmonary arterial pressures, and eventual right ventricular failure. Despite advances in targeted therapies, PAH remains associated with substantial morbidity, reduced functional capacity, impaired quality of life, and increased mortality, with historical survival measured in only a few years without effective treatment.
Learning Objectives
After participating in this education, learners will be able to:
- Implement recommended risk stratification tools into routine assessment of patients with PAH
- Integrate evidence-based combination therapies into the care of appropriate patients with PAH
Speakers
Senior Nurse Practitioner
Yale Pulmonary Vascular Disease Program
New Haven, Connecticut
CE Information
This activity offers 0.25 CME credits to attendees.
Accredited by ACCREDITATION STATEMENT This activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and QDcme. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. .
Disclosures
Ready to start this activity?
Login required. You will be redirected to an external website to register for and complete this activity.
Log in and start activity
